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Abstract: The comparative dynamics and inhibitor binding free energies of group-1 and group-2 pathogenic
inﬂuenza A subtype neuraminidase (NA) enzymes are of fundamental biological interest and relevant to
structure-based drug design studies for antiviral compounds. In this work, we present seven generalized
Born molecular dynamics simulations of avian (N1)- and human (N9)-type NAs in order to probe the
comparative ﬂexibility of the two subtypes, both with and without the inhibitor oseltamivir bound. The
enhanced sampling obtained through the implicit solvent treatment suggests several provocative insights
into the dynamics of the two subtypes, including that the group-2 enzymes may exhibit similar motion in
the 430-binding site regions but different 150-loop motion. End-point free energy calculations elucidate the
contributions to inhibitor binding free energies and suggest that entropic considerations cannot be neglected
when comparing across the subtypes. We anticipate the ﬁndings presented here will have broad implications
for the development of novel antiviral compounds against both seasonal and pandemic inﬂuenza strains.
Introduction
Avian inﬂuenza virus type A, subtype H5N1, is becoming
the world’s largest pandemic threat due to its high virulence
and lethality in birds, quickly expanding host reservoir, and high
rate of mutations.
1 Antigenic drift has given rise to new strains
that are resistant to existing drugs, and antigenic shift is resulting
in new virulent subtypes of the ﬂu virus, underscoring the need
to design novel therapeutics. Inﬂuenza’s two major membrane
glycoproteins, hemagglutinin (HA) and neuramindase (NA),
together play important roles in the interactions with host cell
surface receptors. NA facilitates viral shedding by cleaving
terminal sialic residues on host cell surface proteoglycans, which
are bound by HA.
2
The neuraminidase enzymes are phylogenetically categorized
into two groups: group-1, which includes N1, N4, N5, and N8,
and group-2, which includes N2, N3, N6, N7, and N9.
3 Although
active-site residues are largely conserved across both groups,
different NA subtypes exhibit varied drug susceptibility
4 and
resistance proﬁles.
5,6 Since the ﬁrst NA crystal structure was
published in 1983,
7 a number of structure-based computational
studies against the group-2 subtypes have added signiﬁcant
insight to our understanding of substrate recognition and
inhibitor design. Currently available NA inhibitors, including
oseltamivir
8 and zanamivir,
9 have been designed against crystal
structures of group-2 enzymes (ref 2 and references therein).
Oseltamivir, which has been stockpiled by many nations in
efforts to avert a possible pandemic, is the only orally available
drug effective against H5N1; yet, oseltamivir-resistant strains
have already been isolated.
10,11 These factors combine to easily
motivate additional drug discovery efforts against H5N1.
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our understanding of the binding process. The ﬁrst crystal
structures of a group-1 NA in apo form and in complex with
currently available drugs
12 revealed that, although the binding
pose of oseltamivir was similar to that seen in previous
crystallographic complexes,
7,13 the 150-loop adopted a distinct
conformation, opening a new cavity adjacent to the active site.
Under certain crystallization conditions, however, the 150-loop
adopted the same closed conformation as previously seen in
group-2 NA structures, suggesting a slow conformational change
may occur upon inhibitor binding.
12 It was conjectured that the
new structural observation of the N1 strain’s open 150-loop
could be exploited in structure-based drug discovery efforts.
Despite this detailed structural information, the interpretation
of the loop dynamics based on crystal structures alone is a
difﬁcult task. To complement the crystallographic structures,
all-atom explicit solvent molecular dynamics (MD) simulations
of the apo and oseltamivir-bound systems were carried out.
14
The extensive simulations suggested that the 150-loop and
adjacent binding site loops may be even more ﬂexible than
observed in the crystal structures.
14 In the apo simulations, the
150-loop was seen to open more widely than observed in the
crystal structures, and its motion was often coupled to an
outward movement of the adjacent 430-loop. These coupled
motions signiﬁcantly expanded the active-site cavity, increasing
its solvent-accessible surface area compared with both the open
and closed crystal structures. Subsequent computational solvent
mapping (CS-map) experiments assessed the ability of small,
solvent-sized molecules to bind within close proximity to the
sialic acid binding region and the newly discovered 150- and
430-cavities.
15 The consensus binding sites (i.e., hot spots) of
these probes, as determined by the CS-Map algorithm, have
been shown to relate directly to experimental druggability and
are thus able to identify important binding site features.
16-18
Mapping analyses of the nonredundant MD conformations
revealed the presence of additional hot spot regions in the 150-
and 430-loop regions, conﬁrming the druggability of these newly
revealed sites. Furthermore, small-molecule docking to the new
150- and 430-cavities indicated favorable binding of several
compounds to these areas, in addition to the sialic acid binding
site.
19
A complete understanding of the comparative human- and
avian-type neuraminidase structural dynamics is lacking, despite
the relevance of this knowledge to antiviral development. Our
current understanding of the active-site dynamics for these
medically relevant enzymes is predominantly based on X-ray
crystallography experiments
12 and the aforementioned explicitly
solvated MD simulations of the open 150-loop N1 enzyme. In
this work, in order to assess the dynamical differences in the
150-loop, 430-loop, and sialic acid binding regions between the
avian and human subtypes, we present a series of generalized
Born molecular dynamics (GB MD)
20 simulations of the N1
and N9 NA enzymes. GB MD, which employs a continuum
representation of the solvent water molecules and salt ions, offers
computationalefﬁciencyoverthemorerigorousPoisson-Boltzmann
solvers or explicit solvent simulations.
21 The implicit solvent
approach essentially reduces solvent friction and has been shown
to enhance conformational sampling for a wide variety of
peptide, protein, and nucleic acid systems.
22-25 To date,
however, the application of GB MD to larger biomolecular
systems, such as the neuraminidase enzyme, has been much
fewer in number than its application to smaller proteins and
peptides. This work therefore presents an important method-
ological example that highlights the utility of employing
generalized Born implicit solvent models for elucidating the
dynamics and energetics of large protein systems.
Although crystallographic experiments provide critical time/
ensemble-averaged structure and ligand binding information,
atomic-level simulations yield additional insights and relevant
biophysical information that is otherwise inaccessible with
standard experimental techniques. As oseltamivir does not rely
on water-mediated interactions with the protein active site,
unlike other sialic acid analogue NA inhibitors,
26 the N1 and
N9 oseltamivir-bound systems are particularly well suited for
treatment with implicit solvent. The comparative dynamics that
we present here allow us to gain insights into the ﬂexibility of
the 150- and 430-loops, which are important due to their
proximity to the sialic acid binding site. A more complete
understanding of the dynamical differences between the sub-
types, especially in the 150- and 430-loop regions, may assist
in the design of antiviral compounds that are able to take
advantage of the newly revealed ligand binding areas. Here we
show that the extensive conformational sampling gained through
the GB MD simulations allows us to attain a signiﬁcantly
enhanced conformational sampling speedup, as compared to
explicit solvent MD. The dynamics of residues that have been
shown by computational solvent mapping to be potentially
important in the binding of ligands to this expanded area are
investigated and discussed, and a comparison of the resulting
structures to the explicitly solvated MD simulations is provided.
Finally, end-point free energy calculations provide quantitative
insight into oseltamivir recognition.
Methods
Generalized Born Solvent Simulations. Molecular dynamics
simulations were initiated from crystallographic coordinates. The
seven systems used in our simulations are listed in Table 1. The
closed-loop oseltamivir-bound N1 simulation started from one of
the monomers from the 2HU4 (PDB code) structure. The open-
loop oseltamivir-bound N1 simulation started from one of the
monomers from the 2HTY structure. The closed-loop N9 oselta-
mivir-bound simulation was initiated from one of the monomers
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several residues on the N-terminus were removed (ﬁrst six residues
in N1, V83-N88; ﬁrst nine residues in N9, R82-G90). Coordinates
of the three corresponding apo systems were obtained by removing
the inhibitor oseltamivir, respectively. To study the impact of the
adjacent subunits on loop structure and dynamics, a tetramer system
comprised of the closed-loop N1 neuraminidase in complex with
oseltamivir (2HU4) was also simulated. To compare with experi-
ment, protonation states for histidines and other titratable groups
were determined at pH 6.5 by the PDB2PQR web server and
manually veriﬁed.
27 Hydrogen atoms were added by using the
LEAP module in AMBER. The FF99SB force ﬁeld, which has
modiﬁcations to backbone torsional terms, was used for the
protein.
28 Parameters for oseltamivir were obtained from ANTE-
CHAMBER module using the Generalized Amber force ﬁeld
(GAFF)
29 with RESP HF 6-31G* charges as described previously.
14
All MD simulations were carried out with Amber 8.
30 Temperature
was maintained by using Langevin dynamics with a collision
frequency of 5 ps-1. The time step was 2 fs, and all bonds involving
hydrogen were constrained with the SHAKE algorithm with a
tolerance of 10-4 Å.
Solvation effects were modeled implicitly by using the general-
ized Born model. The GB model has been demonstrated to provide
improved conformational sampling as compared to simulations with
explicit representation of solvent molecules. The improved sampling
arises from an acceleration of transitions due to the lack of solvent
viscosity, as well as through reduced cost of calculating forces of
explicit solvent. A modiﬁed GB model (GBOBC, igb ) 5) was
employed for more accurate solvation of large proteins.
23 The Born
radii were adopted from Bondi with modiﬁcation (mbondi2) and
an offset of 0.09 Å. The scaling factors for Born radii were taken
from the Tinker modeling package. The salt concentration was set
to 0.2 M. A reaction ﬁeld cutoff (rgbmax ) 25 Å) was used to
speed-up the calculation of effective Born radii. No cutoff was used
for the long-range interactions for the monomer systems, while a
cutoff of 50 Å was used for the tetramer system.
Each GB simulation consisted of two stages, equilibration and
production. During equilibration, the starting structure was mini-
mized for 2000 steps to remove close contacts and then gradually
heated to 300 K at 50 K intervals during six simulations of 200 ps.
Positional restraints on backbone atoms were gradually decreased
from 3 to 0 kcal/(mol·Å2) in several stages. All production
simulations were at 300 K and fully unrestrained. Each production
run was ∼16 ns for the monomer systems and ∼5 ns for the tetramer
system. System performance benchmarks are as follows: for the
tetramer system, 0.8 ns per day using 1024 processors on the IBM
BlueGene/L platform at San Diego Supercomputer Center; for the
monomer system, 9 ns per day on the NCSA Abe platform using
256 processors (32 nodes), and 2 ns per day on the IBM BlueGene/L
machine using 256 processors.
Clustering. In order to generate reduced, representative structural
ensembles for the simulations and for the CS-Map calculations,
root-mean-square deviation (RMSD) conformational clustering was
performed, based on a previously reported clustering algorithm.
31
To be able to compare to previous clustering results, the gromos
method within GROMACS (g_cluster) was employed.
33 Structures
were extracted in 10 ps intervals over each of the simulations; 1.6
× 103 trajectory structures for each simulation were superimposed
using all CR atoms to remove overall rotation and translation. The
RMSD-clustering was performed on a subset of 62 residues that
line the entire binding-site area, which we deﬁne here as the
binding-site residues: 117-119, 133-138, 146-152, 156, 179, 180,
196-200, 223-228, 243-247, 277, 278, 293, 295, 344-347, 368,
401, 402, and 426-441. These residues were clustered into batches
of similar conﬁgurations using the atom-positional RMSD of all
atoms (including side chains and hydrogen atoms) as the similarity
criterion. A cutoff of 1.3 Å was chosen on the basis of previous
work using explicit solvent.
15
End-Point Free Energy Calculations. Using equidistant snap-
shots extracted from the GB MD trajectories, the total binding free
energy was computed using the MM-GBSA scheme.
34,35 For
computational efﬁciency, a single trajectory approach was used and
the calculations were performed on ∼800 snapshots with a sampling
interval of 20 ps.
where EMM represents the sum of electrostatic, van der Waals, and
internal energies (we note that the internal energies cancel out in
eq 2 due to the single trajectory approach). ∆Gsolvation is the
desolvation free energy penalty, estimated from GB and solvent-
accessible surface area (SASA) calculations which yield Gpolar and
Gnonpolar. A surface tension coefﬁcient (γ) of 0.0072 kcal/(mol·Å2)
is used to calculate the nonpolar solvation free energy contribution.
The modiﬁed GB model (GBOBC, igb ) 2),
23 the modiﬁed Born
radii (mbondi2), and 0.2 M salt concentration were adopted, to be
consistent with the GB MD simulations. We tried 10 different MM-
PB(GB)SA postprocessing schemes, including IGB5. The best
results (i.e., most closely reproduced experimental binding con-
stants) were obtained with IGB2. T∆S is the product of temperature
(at 300 K) and solute entropy, derived from normal-mode analyses
of the solute coordinates after energy minimization of solute
structures to within a root-mean-square of the energy gradient of
1.0-5 kcal/(mol·Å). The normal-mode analysis was carried out on
eight snapshots at 2 ns sampling intervals due to its prohibitive
computational cost on large protein-ligand systems. The minimum
T∆S results were selected to compute the total binding free energy
in eq 1.
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Table 1. Description of Simulations
a
system name crystal
structure description simulation
time, ns
no. of
atoms
N1ac 2HU4 N1-apo, closed 16 5389
N1ao 2HTY N1-apo, open 16 5389
N1hc 2HU4 N1-holo, closed 15.9 5433
N1ho 2HU0 N1-holo, open 16 5433
N9a 2QWK N9-apo, closed 16 5526
N9h 2QWK N9-holo, closed 16 5568
N1-tetramer 2HU4 N1 tetramer, holo, closed 5 21732
a Seven simulations of the N1 (group-1, avian) and N9 (group-2,
human) neuraminidases are summarized with their system name, initial
PDB structure identiﬁer, brief description, total simulation time, and
number of atoms. The system names listed here are used throughout the
ﬁgures and text.
G ) EMM + ∆Gsolvation - T∆S (1)
∆Gbinding ) Gcomplex - (Greceptor + Gligand) (2)
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The seven simulations with various starting conditions allow
us to investigate the comparative dynamics of the avian- and
human-type neuraminidase enzymes in several states, including
the apo and oseltamivir-bound N1 enzyme starting with the open
150-loop crystal structure (N1ao, N1ho, respectively), the apo
and oseltamivir-bound N1 enzyme starting with the closed 150-
loop crystal structure (N1ac, N1hc), the apo and oseltamivir-
bound N9 crystal structures (N9a, N9h), and the tetramer closed
150-loop oseltamivir-bound N1 (Table 1). As the human-type
N9 enzyme has never been crystallized with the 150-loop in
the open conformation, the starting conditions are with a closed
150-loop. Overall, the backbone RMSD establishes that all of
the systems are stable during the trajectories (Supporting
Information, Figure S1).
RMSD-Based Clustering. An RMSD-based clustering analysis
of 62 residues lining the binding site allows us to compare the
relative structural populations of N1 and N9 in the different
trajectories. The clustering procedure was performed in a manner
identical to that described by Landon et al.
15 (using a 1.3 Å
cutoff) and thus provides a basis of comparison for the explicit
solvent and GB MD simulation cluster structures (Table 2). The
central member structures of the most dominant clusters for each
of the simulations illustrate the range of structural ﬂuctuation
in this loop region (Figure 1). The clustering results indicate
that the GB MD simulations enhance the conformational
sampling of the N1 enzyme, as compared to the explicit solvent
simulations, while maintaining the relative population trends
established in the latter.
The clustering analysis indicates several relevant features of
the N1 dynamics. First, regardless of the open vs closed 150-
loop conﬁguration, the apo systems are more ﬂexible in the
binding-site region compared to the oseltamivir-bound systems.
These results are consistent with the explicitly solvated simula-
tions.
14 Second, the relative cluster populations of the open 150-
loop N1 systems indicate that the GB simulations are able to
sample a larger conformational space than the explicitly solvent
simulations, despite the fact that the GB simulations were 1
order of magnitude shorter in time scale. This is due to the
reduced solvent friction in the GB MD simulations and
highlights the utility of the GB method for exploring receptor
conformational space. In terms of the comparative dynamics
between the N1 and N9 systems, both the N1 and N9 apo
systems are represented by 55 clusters, indicating that the
dynamics are similar between the subtypes in the absence of
substrate. In contrast, the N1hc system has more clusters than
the N9h system, suggesting that the N9 subtype is more stable
than the N1 subtype when oseltamivir is bound.
Active-Site and Hot-Spot Residue Dynamics. The dynamics
of residues lining the sialic acid, 150-, and 430-cavities are of
interest for drug design investigations as well as to better
understand the fundamental basis of molecular recognition in
the neuraminidase enzymes. In order to characterize the dynam-
ics of residues within the N1 and N9 systems, a root-mean-
square ﬂuctuation (RMSF) analysis was performed (Supporting
Information, Figure S2). The dynamics of hot-spot residues
(Table 3; Supporting Information, Figure S3) are of particular
interest, as they have been suggested to provide additional
opportunities for drug discovery that could potentially mitigate
the effects of drug resistance.
15
Our analysis again reveals several interesting features of N1
vs N9 dynamics. Most notably, with the exception of Y406, all
the hot-spot residues lining the sialic acid cavity in N9 exhibit
much lower RMSF values than the same residues in the N1
strain (Table 3). This is also illustrated in the equilibrium binding
poses of oseltamivir, which, in the N9 subtype, undergoes the
least amount of movement from the original crystal structure
pose versus the N1 subtypes (Figure 2). The increased positional
ﬂuctuations of the sialic acid binding residues in the N1 subtype
may contribute to the reduced efﬁcacy of several known
inhibitors against N1.
36,37 In addition, the N9h system shows
(36) Gubareva, L. V.; Webster, R. G.; Hayden, F. G. Antimicrob. Agents
Chemother. 2001, 45, 3403–3408.
Table 2. Clustering Results: Total Number of Clusters at 1.3 Å
RMSD Cutoff for Each System and Number of Clusters
Representing 90% of the Ensemble
system total no. of clusters 90% ensemble
N1ac 55 11
N1ao 85 21
N1hc 36 6
N1ho 39 8
N9a 55 14
N9h 32 6
N1ao - explicit solv 51 10
N1ho - explicit solv 27 5
Figure 1. Motions of the 150- and 430-loops. Loop conformations are
shown in cartoon representation for the most dominant conﬁgurations of
(a) the N1-apo-closed (orange) and the N1-oseltamivir-bound-closed (red),
(b) the N1-apo-open (orange) and the N1-oseltamivir-bound-open (red), and
(c) the N9-apo-closed (orange) and the N9-oseltamivir-bound-closed (red)
trajectories. The N1 open (blue) and N1 closed (green) crystal structures
are shown for comparison.
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oseltamivir (Table 3). The increased rigidity in this area
substantiates available crystallographic data that, to date, have
not provided evidence of 150-loop mobility in the N9 subtype.
The presence of oseltamivir in the closed 150-loop N1 system
actually increases the RMSF of the sialic acid and 150-loop
hot-spot residues (Table 3). This is in contrast to both the open
150-loop N1 and N9 systems, which exhibit reduced ﬂuctuations
in the 150-loop in the presence of oseltamivir. The stabilization
of the 150-loop residues in the N1ho system is in agreement
with the explicitly solvated MD simulations.
14 Taken together,
these ﬁndings suggest relative structural instability of the N1
system in this region due to the presence of inhibitor as
compared to N9, lending support to the potential importance
of targeting the 150- and 430-cavities for developing inhibitors
that bind more strongly to the N1 subtype.
At approximately 6 ns into the N1hc trajectory, a strained
salt bridge forms between R152 and the carboxylate group of
oseltamivir. This salt bridge interaction persists for the remainder
of the simulation. As this interaction is not seen in any of the
other GB or explicit solvent simulations, it is likely that this
salt bridge is an artifact of the continuum solvent approach.
The formation of overstabilized salt bridges, especially those
involving arginine residues, is a known weakness of the GB
model.
38 In all other trajectories, R152, which is within a stable
region of the 150-loop, forms varying salt bridge interactions
with neighboring aspartate residues in the protein. Hot-spot
residue RMSF values for N1hc simulation time segments before
(0-5.2 ns) and after (10.0-15.2 ns) formation of the strained
salt bridge indicate that the positional ﬂuctuations of residues
in the vicinity of R152 are slightly dampened after the salt bridge
is formed (data not shown). The trends in RMSF values for
both time segments, however, are the same as the mean values
reported in Table 3.
Dynamics of the 150- and 430-Loops. The crystal structures
of the N1 enzyme published by Russell et al. ﬁrst revealed the
ﬂexibility of the 150-loop.
12 Adjacent to the sialic acid binding
site, the outward movement of the 150-loop expanded the N1
active site and was suggested to present a new opportunity for
antiviral drug design. Explicitly solvated MD simulations
presented by Amaro et al. sampled a single open-close loop
transition in chain D of the oseltamivir bound system, as
demonstrated by the instantaneous RMSD of the 150-loop from
the closed (2HU4) and open (2HTY) 150-loop crystal structures
during 40 ns of tetramer simulations (Figure 1 in ref 14). In
addition, the explicit MD sampled a so-called “wide-open” 150-
loop structure that signiﬁcantly altered the size and topology
of the N1 binding pocket. In this work, a similar analysis of
the six monomer systems provides dynamical and structural
insights into this region.
For the open 150-loop N1 system, the apo and holo systems
each demonstrate two open-close loop transition events (Figure
3). In comparison to the explicit solvent MD, which sampled
only one transition event in the N1ho system over 160 ns of
simulation, the four loop transition events sampled here point
to the advantage of the GB method for sampling conformational
transitions on a much faster time scale compared to explicit
solvent MD. Similar to the explicit solvent MD, the most
dominant central member cluster structure of the N1 apo system
is signiﬁcantly more open than the open 150-loop crystal
structure (Figure 1). The general agreement between the
resulting structures determined by both computational methods
substantiates the idea that the N1 subtype generally exists in a
more open conformation in the absence of ligand. By contrast,
the closed 150-loop N1 systems remain relatively stable across
the trajectories, and no loop transition events are sampled (Figure
3).
In the (closed-loop) apo N9 system, the open-close loop
transition analysis indicates that the enzyme adopts an inter-
mediate conformation (Figure 3). This is also illustrated in the
most dominant cluster representative structure, which indicates
that the 150-loop in the apo N9 system takes on characteristics
of both the closed and open loops but is deﬁnitively more open.
Our analysis indicates that the most populated structure in the
N9a system has an open 150-cavity. This structural ﬁnding
suggests that, in the absence of inhibitor, both subtypes take
on a more relaxed and open conformation in the 150-loop region.
In contrast, the holo N9 system remains in a more closed
conformation throughout (Figures 1 and 3).
It is also worth noting that, in each of the most dominant
structures extracted from all six monomer simulations, the 430-
loop adopts a more open conformation (Figure 1). These results
reveal motion in the 430-loop region for the N9 enzyme and,
more broadly, indicate that motion in the 430-loop region is
independent of bound ligand. Importantly, this suggests that
compounds designed to target the more open 430-cavity have
the potential to be viable against both N1 and N9 subtypes.
End-Point Free Energy Calculations. In order to quantify the
individual contributions to oseltamivir binding in the N9 and
N1 systems, end-point energy calculations were performed. The
theory of end-point energy, also known as MM-PB(GB)SA,
calculations relies on a set of assumptions, elegantly reviewed
in ref 39. A simple thermodynamic cycle and single-trajectory
postprocessing allows the efﬁcient computation of the various
contributions. Here, the application of the MM-GBSA approach
(37) McKimm-Breschkin, J.; Trivedi, T.; Hampson, A.; Hay, A.; Klimov,
A.; Tashiro, M.; Hayden, F.; Zambon, M. Antimicrob. Agents
Chemother. 2003, 47, 2264–2272.
(38) Geney, R.; Layten, M.; Gomperts, R.; Hornak, V.; Simmerling, C.
J. Chem. Theory Comput. 2006, 2, 115–127.
Table 3. RMSF per Hot-Spot Residue for the Six Simulations
a
N1ao N1ac N1ho N1hc N9a N9h
Sialic Acid Region
R 118 0.57 0.54 0.51 0.51 0.42 0.48
E 119 0.56 0.55 0.65 0.61 0.44 0.48
R 224 0.47 0.49 0.48 0.61 0.42 0.43
E 227 0.48 0.53 0.52 0.65 0.44 0.45
S 246 1.13 1.01 1.02 1.31
E 277 0.57 0.6 0.49 0.56 0.47 0.41
R 371 0.77 0.78 0.83 0.8 0.79 0.73
Y 406 0.47 0.55 0.48 0.54 1 0.55
150-Loop Region
V 116 0.68 0.64 0.49 0.69 0.51 0.55
Q 136 0.81 0.74 0.87 0.77 0.78 0.79
V 149 2.31 1.53 1.21 2.82
D 151 1.52 0.99 0.71 1.66 0.98 0.69
R 152 1.26 0.96 0.79 1.32 0.95 0.79
S 153 1.22 0.94 0.83 1.23 0.97 0.85
P 154 1.24 0.98 0.93 1.22
R 156 0.69 0.64 0.59 0.62 0.54 0.59
W 178 0.56 0.5 0.77 0.57 0.44 0.44
S 179 0.48 0.47 0.66 0.51 0.4 0.41
S 195 0.64 0.6 0.64 0.79 0.54 0.56
G 196 0.77 0.76 0.81 1.19 0.72 0.74
a The ﬁrst column lists the residue type, the second column lists the
residue number, and the third through eighth columns list the RMSF per
residue for the N1-apo-open, N1-apo-closed, N1-holo-open,
N1-holo-closed, N9-apo, and N9-holo systems, respectively.
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binding while providing relative free energies of binding that
correlate well with experimental data for both N9 and N1
subtypes (Table 4).
36,37,40 The absolute values of the binding
free energies, however, are off by approximately 5-7 kcal/mol
in all three cases, which is not surprising given the assumptions
present in the underlying theory and also considering that we
neglected to include the internal energy change (i.e., strain
energy) for oseltamivir binding. Regarding the latter, Masukawa
et al. showed that the range of ligand strain energy may be in
the range of -5 to 5 kcal/mol for known inhibitors of NA,
although they recognized the inherent difﬁculty in determining
accurate absolute quantities due to insufﬁcient sampling.
26
In theory, if the conﬁgurational space sampling is sufﬁcient, the
N1 open- and closed-loop systems should converge to the same
binding free energy, since they are the same enzyme (merely
different starting conﬁgurations of the 150-loop). Although our
results are not identical between the two systems, it is promising
that they are within the standard error of the mean for each. A
plot of the convergence of the binding free energies as a function
of trajectory length indicates that the differences between running
1 and 16 ns in terms of the enthalpic contributions are minor
(Supporting Information, Figure S4). It also indicates that the salt
bridge artifact between R152 and oseltamivir in the N1hc system
(which was not present before 6 ns) has a negligible effect on the
binding free energy.
The absolute values of the electrostatics terms are similar to
those recently published by Chachra and Rizzo for the N1
system, using explicit solvent simulations.
41 Although they and
(39) Swanson, J. M. J.; Henchman, R. H.; McCammon, J. A. Biophys. J.
2004, 86, 67–74.
(40) Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan,
Y.; Lin, T.-H.; Hutchison, T. L.; Elliott, A. J.; Parker, C. D.; Ananth,
S. L.; Horn, L. L.; Laver, G. W.; Montgomery, J. A. J. Med. Chem.
2000, 43, 3482–3486.
(41) Chachra, R.; Rizzo, R. C. J. Chem. Theory Comput. 2008, 4, 1526–
1540.
Figure 2. Equilibrium orientations of oseltamivir in the different binding sites. Overall orientations (left panel) and active-site interactions (right panel) of
oseltamivir bound to (a) the N1-closed, (b) the N1-open, and (c) the N9-closed system. The original conformations of the 150- and 430-loops are shown in
blue and red, respectively, to highlight the loop motion observed in the course of the dynamics. Active-site residues within4Åo foseltamivir are shown
explicitly. The original conformation of oseltamivir is shown in violet for comparison.
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42-44 have shown that within a single NA enzyme, the
electrostatics term trends well with experimental binding free
energies, our results suggest this is not the case when comparing
across human and avian subtypes. Notably, it is only with the
inclusion of the entropic component that the free energies of
binding agree with what is known experimentally (Table 4).
Our work indicates that the N1 systems (whether initiated from
a closed- or open-150 loop) pay a larger entropic penalty upon
binding oseltamivir. These results are in good correspondence
with the loop transition sampling events (Figure 3) and the per-
residue RMSF values (Table 3), which indicate increased
ﬂexibility in the N1 subtype. Thus, we would expect the N1
systems to pay a higher entropic penalty upon complexation
(42) Taylor, N. R.; von Itzstein, M. J. Comput. Aided Mol. Des. 1996, 10,
233–246.
(43) Bonnet, P.; Bryce, R. A. J. Mol. Graph. Modell. 2005, 24, 147–156.
(44) Armstrong, K. A.; Tidor, B.; Cheng, A. C. J. Med. Chem. 2006, 49,
2470–2477.
Figure 3. Open-closed loop transitions. Root-mean-square deviations of the 150-loop (comprising residues N146-R152) from the MD with respect to the
open (gray) and closed (black) crystal structures are shown for the N1-apo-closed (a), the N1-oseltamivir-bound-closed (b), the N1-apo-open (c), the N1-
oseltamivir-bound-open (d), the N9-apo-closed (e), and the N9-oseltamivir-bound-closed (f) structures.
Table 4. End-Point Free Energy Calculations with MM-GBSA
a
contribution N9 N1-open N1-closed
∆Eelec -189.2 (0.6) -210.2 (1.0) -205.5 (0.6)
∆EVDW -24.2 (0.2) -24.8 (0.2) -26.8 (0.2)
∆Gsolv,polar 173.2 (0.6) 193.0 (0.8) 186.7 (0.5)
∆Gsolv,nonpolar -5.1 (0.01) -5.0 (0.01) -5.1 (0.01)
-T∆S(vib) -0.2 5.3 9.6
-T∆S(total) 23.6 29.2 33.5
∆Gbinding -21.7 (0.8) -17.8 (1.2) -17.1 (0.8)
∆Gbinding,exp -15.2 to -12.0 -13.3 to -12.8 -13.3 to -12.8
a The average contributions to the oseltamivir binding free energies to
the N9, N1-open, and N1-closed systems over the 16 ns trajectories are
given in kcal/mol; standard errors of the mean are given in parentheses.
∆Eelec and ∆EVDW are the molecular mechanics electrostatic and van der
Waals contributions, respectively. ∆Gsolv, polar is the polar component of
the solvation free energy, whereas ∆Gsolv, nonpolar is the nonpolar
component. T∆S is the contribution from the rotational (rot),
translational (trans), and vibrational (vib) entropies. Experimental
binding free energies (∆Gbinding, exp) are provided for comparison..
36,37,40
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intrinsically less ﬂexible. Future antiviral development efforts
against the N1 subtype may beneﬁt from considering these
entropic contributions.
Tetramer GB MD Simulations. As a control for our monomer
simulations, we also present data froma5n sG Bsimulation of
the closed 150-loop N1 tetramer system. The tetramer system,
with 21 732 atoms (Table 1), exhibited excellent parallel
performance scaling: we were able to generate 0.8 ns per day
when scaled to 1024 processors on the IBM BlueGene machine
at the San Diego Supercomputer Center.
The comparison of the tetramer N1hc system to the monomer
N1hc system reveals largely similar behavior, especially in the
sialic acid, 150-, and 430-loop regions. The open-close loop
transition behavior was also similar for each of the monomers
within the tetramer (Figure 3; Supporting Information, Figure
S5). Neither of the closed-loop systems exhibits signiﬁcant
motion in the 150-loop. The exception is chain B of the tetramer,
in which the 150- and 430-loops (data not shown) shift to a
more open conformation after ∼ 3 ns. Notably, the interaction
of R152 with the carboxylate group of oseltamivir occurs in
two of the four chains of the tetramer, indicating the intermittent
occurrence of this interaction. We anticipate that this extended
arginine interaction may occur in all four chains if the tetramer
simulations were run for longer than 5 ns. Again we note that
this salt bridge is likely overstabilized and could be an artifact
of the GB electrostatics.
A comparison of the RMSF difference per residue of the
tetramer to the monomer systems does indicate slight structural
variation between the simulations in a region far from the active
site. In particular, in the monomer simulations, a helix on the
opposite side of the 430-loop, comprised of residues D103-F115
(hereafter referred to as the “110-helix”), exhibited larger RMSF
values (Supporting Information, Figure S6) and in several cases
appeared to completely unravel. In the physiologically relevant
tetrameric form of the enzyme, the 110-helix makes contact to
a neighboring subunit. Correspondingly, in the tetramer simula-
tion, the contacts formed among the subunits appear to stabilize
this region. The percentage of secondary structure formed (R
helix) within the core of this 110-helix (residues S105-G109)
as a function of simulation time was investigated (Table 5 and
Figure S6) and indicates that the tetrameric contacts play a role
in stabilizing this region of the enzyme. Although the tetramer
simulation was performed only for the N1 enzyme, we expect
similar results for the N9 subtype. Recent explicit solvent
simulations of the monomer form of the N9 subtype also indicate
that restrained dynamics were necessary to maintain the proper
backbone fold,
41 whereas explicit solvent simulations of the
tetramer enzyme were stable.
14 Our work here supports these
observations, although the increased structural ﬂuctuations are
localized to the 110-helix and the termini strand, not generaliz-
able to the entire protein backbone.
Conclusions
This study points to the promise and utility of generalized
Born implicit solvent models for elucidating the dynamics and
energetics of large-scale atomistic protein systems. The reduced
solvent friction in the simulations enhances the receptor
conformational space sampling for the N1 and N9 neuraminidase
enzymes, as compared to explicitly solvated MD simulations.
The 16 ns GB MD trajectories sample twice as many open-close
loop transition events as compared to 160 ns of explicit solvent
simulations, suggesting a conformational sampling speed-up of
at least 10 times that of equivalent explicit solvent simulations.
Our work also shows that end-point free energy calculations
performed with the MM-GBSA protocol are able to recapture
experimentally known oseltamivir binding proﬁles, thus provid-
ing an important computational framework to understand the
various contributions to substrate recognition in the neuramini-
dase enzymes. Moreover, our estimates of the entropic contribu-
tions to the binding free energies suggest that these contributions
cannot be neglected when comparing binding afﬁnities across
the subtypes.
This work also provides several provocative insights into the
structural dynamics of the avian- and human-type NA enzymes,
including that the apo N9 enzyme may also present 150- and
430-cavities to antiviral compounds. Especially promising is the
persistence of the open 430-cavity in both the oseltamivir-bound
and apo systems. Consequently, we anticipate that novel antiviral
compounds targeting the recently discovered 150- and 430-
cavities in the N1 subtype may also be effective against N9,
and we suggest the targeting of these new pockets as a general
anti-inﬂuenza drug development strategy. This could have
important implications for developing new therapeutics that
maintain efﬁcacy over currently known resistant strains, for both
seasonal and potentially pandemic inﬂuenza subtypes.
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Table 5. Comparison of the 110-Helix Helical Character for the
Tetramer and Monomer Simulations
R helix (%) 3-10-helix (%)
tetramer chain A 63.6 25.6
tetramer chain B 54.9 33.9
tetramer chain C 67.3 25.6
tetramer chain D 47.8 19.7
monomer 17.7 16.1
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